MX2023012826A - Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. - Google Patents

Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.

Info

Publication number
MX2023012826A
MX2023012826A MX2023012826A MX2023012826A MX2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A MX 2023012826 A MX2023012826 A MX 2023012826A
Authority
MX
Mexico
Prior art keywords
treatment
receptor antagonists
endothelin receptor
ocular diseases
diseases
Prior art date
Application number
MX2023012826A
Other languages
English (en)
Inventor
Cheng - Wen Lin
Sevgi Gurkan
Angela Dawn Glendenning
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of MX2023012826A publication Critical patent/MX2023012826A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se relaciona con el descubrimiento de que ciertas enfermedades del ojo que afectan profundamente el sistema visual humano y, como resultado, la calidad de vida, pueden tratarse usando Edonentan o A-182086. Los ejemplos de las enfermedades incluyen, pero no se limitan a, neovascularización ocular, glaucoma neovascular, fuga vascular, edema macular y degeneración macular neovascular relacionada con la edad.
MX2023012826A 2021-04-30 2022-04-29 Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. MX2023012826A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182750P 2021-04-30 2021-04-30
PCT/US2022/027045 WO2022232586A1 (en) 2021-04-30 2022-04-29 Treatment of ocular diseases using endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
MX2023012826A true MX2023012826A (es) 2023-11-13

Family

ID=83848733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012826A MX2023012826A (es) 2021-04-30 2022-04-29 Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.

Country Status (9)

Country Link
US (1) US20240058265A1 (es)
EP (1) EP4329810A1 (es)
JP (1) JP2024516829A (es)
CN (1) CN117295520A (es)
AU (1) AU2022264438A1 (es)
CA (1) CA3218398A1 (es)
IL (1) IL307794A (es)
MX (1) MX2023012826A (es)
WO (1) WO2022232586A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087864A1 (en) * 2010-04-12 2012-04-12 R-Tech Ueno, Ltd. Method for diagnosing and/or evaluating retinal disease
JP2017519813A (ja) * 2014-05-23 2017-07-20 オキュラー テクノロジーズ エスアーエールエル 局所製剤およびその使用
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
CN114786480B (zh) * 2019-10-30 2024-03-29 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病

Also Published As

Publication number Publication date
CA3218398A1 (en) 2022-11-03
JP2024516829A (ja) 2024-04-17
EP4329810A1 (en) 2024-03-06
CN117295520A (zh) 2023-12-26
IL307794A (en) 2023-12-01
AU2022264438A1 (en) 2023-11-23
WO2022232586A1 (en) 2022-11-03
US20240058265A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MX347226B (es) Tratamiento de enfermedad ocular.
MX2017005204A (es) Dispositivos y métodos de estimulación para tratar el ojo seco.
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
EA200700772A1 (ru) Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний
MX2023011426A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
GB201918994D0 (en) Treatments of diabetic macular edema and impaired visual acuity
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
WO2018136669A3 (en) Therapeutic and neuroprotective peptides
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
IL287758A (en) Anti-sema3a antibodies and their use for the treatment of eyes or eye diseases
MX2020007948A (es) Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
MX2019012012A (es) Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
ZA202204939B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2023012826A (es) Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
RU2010135224A (ru) Способ хирургического лечения макулярного отека после факоэмульсификации катаракты
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
EP3823603A4 (en) OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES AND SKIN DISEASES